BioAtlaBCAB
About: BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Employees: 65
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
500% more call options, than puts
Call options by funds: $78K | Put options by funds: $13K
5% less funds holding
Funds holding: 83 [Q1] → 79 (-4) [Q2]
10.04% less ownership
Funds ownership: 56.02% [Q1] → 45.98% (-10.04%) [Q2]
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
41% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 29
67% less capital invested
Capital invested by funds: $92.1M [Q1] → $30.4M (-$61.7M) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
JMP Securities Reni Benjamin 25% 1-year accuracy 5 / 20 met price target | 170%upside $5 | Market Outperform Reiterated | 16 Sept 2024 |
Financial journalist opinion
Based on 6 articles about BCAB published over the past 30 days